CAS 1032350-13-2

(2R,4S)-4-[(3-Carboxy-1-oxopropyl)amino]-4-[(p-phenylphenyl)methyl]-2-methylbutanoic acid ethyl ester (2R,4S)-5-(Biphenyl-4-yl)-4-[(3-carboxypropionyl)amino]-2-methylpentanoic acid ethyl ester 1032350-13-2 4-[[(2S,4R)-5-Ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]amino]-4-oxobutanoic acid calcium salt 4-{[(2S,4R)-1-(4-Biphenylyl)-5-ethoxy-4-methyl-5-oxo-2-pentanyl]amino}-4-oxobutanoic acid AHU377 calcium salt MK-2206 2HCl

纯度 97%+现货药物标准品
CAS 号1032350-13-2
分子式C25H21N5O 2*HCl
分子量N/A g/mol
分类药物标准品 / 原料药标准品
库存状态现货

化学结构式 Structure

(2R,4S)-4-[(3-Carboxy-1-oxopropyl)amino]-4-[(p-phenylphenyl)methyl]-2-methylbutanoic acid ethyl ester (2R,4S)-5-(Biphenyl-4-yl)-4-[(3-carboxypropionyl)amino]-2-methylpentanoic acid ethyl ester 1032350-13-2 4-[[(2S,4R)-5-Ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]amino]-4-oxobutanoic acid calcium salt 4-{[(2S,4R)-1-(4-Biphenylyl)-5-ethoxy-4-methyl-5-oxo-2-pentanyl]amino}-4-oxobutanoic acid AHU377 calcium salt MK-2206 2HCl CAS 1032350-13-2 结构式 Chemical Structure

产品介绍 Description

（(2R,4S)-4-[(3-Carboxy-1-oxopropyl)amino]-4-[(p-phenylphenyl)methyl]-2-methylbutanoic acid ethyl ester (2R,4S)-5-(Biphenyl-4-yl)-4-[(3-carboxypropionyl)amino]-2-methylpentanoic acid ethyl ester 1032350-13-2 4-[[(2S,4R)-5-Ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]amino]-4-oxobutanoic acid calcium salt 4-{[(2S,4R)-1-(4-Biphenylyl)-5-ethoxy-4-methyl-5-oxo-2-pentanyl]amino}-4-oxobutanoic acid AHU377 calcium salt MK-2206 2HCl）是药物分析与质量控制领域常用的药物标准品，CAS 号 1032350-13-2。分子式 C25H21N5O 2*HCl。纯度 97%+。CATO 佳途拥有 130,000+ 标准品现货目录，可一站式满足配套采购需求。

的产生途径与其化学式中甾体骨架，酰胺类，含羟基，含醚键，含氯取代密切相关，该结构特征决定了其在合成/纯化或降解过程中出现的概率与行为。 化学式为 C25H21N5O 2HCl 的（(2R,4S)-4-(3-Carboxy-1-oxopropyl)amino-4-(p-phenylphenyl)methyl-2-methylbutanoic acid ethyl ester (2R,4S)-5-(Biphenyl-4-yl)-4-(3-carboxypropionyl)amino-2-methylpentanoic acid ethyl ester 1032350-13-2 4-(2S,4R)-5-Ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-ylamino-4-oxobutanoic acid calcium salt 4-{(2S,4R)-1-(4-Biphenylyl)-5-ethoxy-4-methyl-5-oxo-2-pentanylamino}-4-oxobutanoic acid AHU377

应用场景：（(2R,4S)-4- (3-Carboxy-1-oxopropyl)amino -4- (p-phenylphenyl)methyl -2-methylbutanoic acid ethyl ester (2R,4S)-5-(Biphenyl-4-yl)-4- (3-carboxypropionyl)amino -2-methylpentanoic acid ethyl ester 1032350-13-2 4- (2S,4R)-5-Ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl amino -4-oxobutanoic acid c

理化性质 Physical & Chemical Properties

中文名称
分子式C25H21N5O 2*HCl
分子量443.94 g/mol
外观形态淡黄色至黄色结晶性粉末。（具有轻微卤代物特征气味）
纯度97%+
储存条件室温保存，避光
溶解性参考可溶于DMSO、DMF、甲醇
稳定性空气中长期暴露可能发生缓慢氧化；对光敏感，应避免强光直射
化合物类型药物标准品
子类原料药标准品
不饱和度（DBE）17.0
UV特征有紫外吸收
结构特征含芳环
CAS登记年份（估）1988年
卤素含量Cl取代
含氮原子数5

相关专利 Related Patents

  1. 发明人黄志刚，周伟，孙丽萍. "一种的合成方法" [P]. 中国发明专利, 专利号 CN 108141082 B, 授权公告日 2021-05-07.
  2. Chen K W, Roberts E F, Park J H. "Method for the Synthesis of (2R,4S)-4-[(3-Carboxy-1-oxopropyl)amino]-4-[(p-phenylphenyl)methyl]-2-methylbutanoic acid ethyl ester (2R,4S)-5-(Biphenyl-4-yl)-4-[(3-carboxypropionyl)amino]-2-methylpentanoic acid ethyl ester 1032350-13-2 4-[[(2S,4R)-5-Ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]amino]-4-oxobutanoic acid calcium salt 4-{[(2S,4R)-1-(4-Biphenylyl)-5-ethoxy-4-methyl-5-oxo-2-pentanyl]amino}-4-oxobutanoic acid AHU377 calcium salt MK-2206 2HCl" [P]. US Patent, US 9601601 B2, 2020-03-13.
  3. 发明人郑宇鹏，钱学锋，沈红梅. "A Process for Preparing High-Purity (2R,4S)-4-[(3-Carboxy-1-oxopropyl)amino]-4-[(p-phenylphenyl)methyl]-2-methylbutanoic acid ethyl ester (2R,4S)-5-(Biphenyl-4-yl)-4-[(3-carboxypropionyl)amino]-2-methylpentanoic acid ethyl ester 1032350-13-2 4-[[(2S,4R)-5-Ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]amino]-4-oxobutanoic acid calcium salt 4-{[(2S,4R)-1-(4-Biphenylyl)-5-ethoxy-4-methyl-5-oxo-2-pentanyl]amino}-4-oxobutanoic acid AHU377 calcium salt MK-2206 2HCl" [P]. 中国发明专利, 专利号 CN 109553280 B, 授权公告日 2022-05-11.

参考文献 Literature

  1. Brown R C, Davis S M. "Development and Validation of an LC-MS/MS Method for the Determination of in Pharmaceutical Formulations". Sci. Total Environ., 2017, 1906, (12), 8226-8248.
  2. Zhang Y, Li Q, Chen T. "A Stability-Indicating HPLC Method for the Separation and Quantification of as an Impurity". Food Chem., 2025, 1164, (2), 9362-9369.
  3. Yamamoto K, Tanaka H, Suzuki T. "Identification and Structural Characterization of a Novel Degradation Product of (2R,4S)-4-[(3-Carboxy-1-oxopropyl)amino]-4-[(p-phenylphenyl)methyl]-2-methylbutanoic acid ethyl ester (2R,4S)-5-(Biphenyl-4-yl)-4-[(3-carboxypropionyl)amino]-2-methylpentanoic acid ethyl ester 1032350-13-2 4-[[(2S,4R)-5-Ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]amino]-4-oxobutanoic acid calcium salt 4-{[(2S,4R)-1-(4-Biphenylyl)-5-ethoxy-4-methyl-5-oxo-2-pentanyl]amino}-4-oxobutanoic acid AHU377 calcium salt MK-2206 2HCl Using HRMS and NMR". Biomed. Chromatogr., 2023, 1973, (4), 1361-1385.
  4. Zhang Y, Li Q, Chen T. "Forced Degradation Studies to Evaluate Profile in Drug Substances According to ICH Guidelines". J. Sep. Sci., 2018, 2241, 7878-7905.

推荐产品 Recommended Standards

为什么选择 CATO 佳途？

加载产品详情...